April 12, 2022 8:52am

Another indication, the aftermarket was weak although a few sector equities are flashing upside benefit

Pre-open indications: 4 BUYS, 3 SELLs and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.41% (+140 points), S&P futures are UP +0.72% (+32 points) and NASDAQ futures are UP +1.35% (+189 points)


U.S. stock futures were moving up on Tuesday as investors braced for a super spike of an inflation report,

European markets sank Tuesday morning as traders monitored heavy selling in the banking sector, and looked ahead to key central bank meetings and U.S. inflation prints,

Asia-Pacific stocks were mixed after developments surrounding the major surge and lockdown in Covid population in mainland China as well as movements in the Japanese yen’s value against the dollar.



The Dow closed DOWN -413.04 points (-1.19%); the S&P closed DOWN -75.75 points (-1.69%) while the Nasdaq closed DOWN -299.04 points (-2.18%)

Economic Data Docket:  March’s highly anticipated consumer price index. The data showed an 8.5% annual increase in prices — the highest level since December 1981 


RegMed Investors’ (RMi) closing bell: “dancing the limbo, how low have the cell and gene therapy sector fallen - five (5) sessions in a row.” … https://www.regmedinvestors.com/articles/12383

Ebb and flow –

Q2/22 – 1 positive and 5 negative close


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes



Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …


Caribou Biosciences (CRBU) closed down again -$0.32 to $7.94 after Friday’s -$0.06 and Thursday’s -$0.39 with a positive +$0.42 or +5.29% pre-open indication.

BioLife Solutions (BLFS) closed down again -$0.38 to $19.84 after Friday’s -$1.69, Thursday’s -$0.05, Wednesday’s -$0.84 and last Tuesday’s -$1.40 with a positive +$0.37 or +1.86% pre-open indication. A new “name” auditor, Grant Thornton after a late 10-K (annual report) and SEC non-compliance action.

Sage Therapeutics (SAGE) closed down -$1.26 to $35.20 with a positive +$0.92 or +2.61% pre-open indication.

Verastem (VSTM) closed down -$0.04 to $1.52 with a positive +$0.15 or +9.87% pre-open indication.



Alnylam Pharmaceuticals (ALNY) closed down -$5.99 to $157.43 with a negative -$0.26 or -0.17% pre-open indication.

Chinook Therapeutics (KDNY) closed down -$0.24 to $15.19 with a negative -0.75 or -4.94% pre-open indication.

Ionis Pharmaceuticals (IONS) closed down -$0.51 to $39.61 with a negative -$0.98 or -$2.47% pre-open indication.


Pimp/Pump and Promote:

Biostage (BSTG) closed flat with 25 shares traded after Friday’s +$0.50 with 3,139 shares traded, Thursday’s -$0.63 to $5.30, Wednesday’s -$0.05 with 1,527 shares traded and last Tuesday’s +$0.59 with 8,743 shares trading.

  • WARNING:  WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.


The BOTTOM LINE: Draining liquidity has impeded any shares pricing expectation as we are caught in a volatility trap.

Worst session in more than a while as the oversold are even more undervalued.

I STILL believe, lows are looking appetizing after going as even to LOWER levels on Monday.

52-week or all-time lows: just a few …

  • Applied Genetic Technologies (AGTC) at $1.00
  • AVROBIO (AVRO) at $1.14
  • Adverum Biotechnologies (ADVM) at $1.17
  • Caribou Biosciences (CRBU) at $7.94
  • Homology Medicine (FIXX) at $2.34
  • Beam Therapeutics (BEAM) at $49.01

I stated on the Friday a.m. post: “Be bold for the oversold. Lows are looking appetizing, as an upside reversal found support of key levels on Thursday.”

It didn’t quite hurdle the resistance after the week’s four (4) negative closes.

Even I expected the oversold to at the least gain some altitude. I can write that I was wrong but, it’s all also about being … EARLY.

I am more than worried about pricey valuations that (in my mind’s eye) have NO basis.

The oversold need chance to appreciate from being oversold.

My version of a relevant quote from Barrons, “The summer of the stock market’s discontent might have started early, with a negative first quarter that perhaps anticipated the May-to-November stretch that historically is the worst six-month period for equity investors. Next month also begins the half-year ahead of the midterm elections, the weakest six months for stocks in the presidential cycle.”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.